Common Drugs with Effective Off-Label Uses

Main Article Content

Mohammed M. Alshehri
Mahmoud M. E. Mudawi

Abstract

The term off-label drug use (OLDU) is utilized broadly in the medical literature. It is a polarizing term since it may be related to incredible advantage or harm to patients. OLDU is defined as drug uses that not included in the indications or dosage regimens listed in the drug labeling. The main issue with off-label use is that there is insufficient information supports the use of the drug so this review aims to give brief information about some common drugs with effective and useful off-label uses based on scientific study and to encourage the researcher to provide sufficient information for the physician and health care providers about off-label uses to decrease the risk of harm to the patients. There are many drugs with various off-label uses that play an important role clinically such as using atorvastatin in chronic heart failure (CHF) due to its pleiotropic action also it can show a significant reduction in the frequency of hospitalization due to CHF exacerbation. However, that make off-label uses an important is several diseases do not have approved drugs, partly because the diseases are rare or conducting clinical trials and marketing the drug for such diseases may not be gainful.

Keywords:
Off-label drug use, the benefit of off-label uses, atorvastatin, aspirin

Article Details

How to Cite
Alshehri, M. M., & Mudawi, M. M. E. (2020). Common Drugs with Effective Off-Label Uses. Journal of Pharmaceutical Research International, 32(10), 25-33. https://doi.org/10.9734/jpri/2020/v32i1030490
Section
Review Article

References

Wittich Christopher M, Burkle Christopher M, Lanier William L. Ten common questions (and their answers) about off-label drug use. In: Mayo Clinic Proceedings. Elsevier. 2012;982-990.‏

Zheng Zhihua, Yang Min, Wu Junyan. Ethical off-label drug-use: Need for a rethink? Indian Pediatrics. 2017;54(6):447-450.‏

Carvalho Marisa Lima. Challenges on off label medicine use. Revista Paulista de Pediatria. 2016;34(1):1-2.‏

Narayanan Raja, Honavar Santosh G. A tale of two drugs: Off and on-label. Indian Journal of Ophthalmology. 2017;65(7):549.‏

Gota Vikram, Divatia Jigeeshu V. Off-label use of drugs: An evil or a necessity? Indian Journal of Anesthesia. 2015;59(12):767.‏

Abbott Ryan, Ayres Ian. Evidence and extrapolation: Mechanisms for regulating off-label uses of drugs and devices. Duke LJ. 2014;64:377.‏

Stolfi Carmine, et al. Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. International Journal of Molecular Sciences. 2013;14(9):17972-17985.‏

Sekar KC, Corff KE. Treatment of patent ductus arteriosus: Indomethacin or ibuprofen? Journal of Perinatology. 2008;28(1):S60-S62.‏

Gulack Brian C, et al. Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus. Early Human Development. 2015;91(12):725-729.‏

Stancu Camelia, Sima Anca. Statins: Mechanism of action and effects. Journal of Cellular and Molecular Medicine. 2001;5(4):378-387.‏

Generali Joyce A, Cada Dennis J. Atorvastatin: Rheumatoid arthritis. Hospital Pharmacy. 2009;44(3):232-233.‏

Hung Chen-Ying, et al. Statin therapy for primary prevention of atrial fibrillation: Guided by CHADS2/CHA2DS2VASc score. Korean Circulation Journal. 2014;44(4):205-209.‏

Shi Rui, et al. Effects of lipid-lowering agents on diabetic retinopathy: A meta-analysis and systematic review. International Journal of Ophthalmology. 2018;11(2):287.‏

Szyguła-Jurkiewicz Bożena, et al. The role of statins in chronic heart failure. Kardiochirurgia i torakochirurgia polska= Polish Journal of Cardio-Thoracic Surgery. 2014;11(3):301.‏

Cadavid Angela P. Aspirin: The mechanism of action revisited in the context of pregnancy complications. Frontiers in Immunology. 2017;8:261.‏

Pasche Boris, et al. Prevention and treatment of cancer with aspirin: where do we stand? In: Seminars in Oncology. WB Saunders. 2014;397-401.‏

Rodríguez Luis A, García, et al. New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: A nested case-control study in UK general practice. BMC Cancer. 2017;17(1):637.‏

MB, Michael PJ, Devile BSC. Antiplatelet drugs, coronary stents and non-cardiac surgery. Continuing Education in Anaesthesia, Critical Care & Pain. 2010;10(6).‏

Mahmoud Ahmed N, et al. Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. PloS One. 2017;12(4).‏

Hsieh Kai-Sheng, et al. Treatment of acute Kawasaki disease: Aspirin’s role in the febrile stage revisited. Pediatrics. 2004;114(6):e689-e693.‏

Atallah A, et al. Aspirin for prevention of preeclampsia. Drugs. 2017;77(17):1819-1831.‏

Sawanyawisuth Kittisak, et al. Aspirin therapy as primary prevention in hypertensive patients at Srinagarind hospital. Journal-Medical Association of Thailand. 2005;88(12):1797.‏

Wang Liping, et al. Efficacy evaluation of low-dose aspirin in IVF/ICSI patients evidence from 13 RCTs: A systematic review and meta-analysis. Medicine. 2017;96(37).

Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin‐induced flushing. International Journal of Clinical Practice. 2009;63(9): 1369-1377.‏

Gorre Frauke, Vandekerckhove Hans. Beta-blockers: Focus on mechanism of action which beta-blocker, when and why? Acta Cardiologica. 2010;65(5):565-570.‏

Steenen Serge A, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology. 2016;30(2):128-139.‏

Rojas Yesenia, et al. Burns: An update on current pharmacotherapy. Expert Opinion on Pharmacotherapy. 2012;13(17):2485-2494.‏

Cheng Jin-Wei, et al. Meta-analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. World Journal of Gastroenterology: WJG. 2003;9(8):1836.‏

Taksande A, et al. Hypercyanotic spells. J Mahatma Gandhi Inst Med Sci. 2009;14:7-9.‏

Idrose Alzamani Mohammad. Acute and emergency care for thyrotoxicosis and thyroid storm. Acute Medicine & Surgery. 2015;2(3):147-157.‏

Reid Jeri R, Wheeler Stephen F. Hyperthyroidism: Diagnosis and treatment. American Family Physician. 2005;72(4): 623-630.‏

Baillie J. Kenneth, Power I. The mechanism of action of gabapentin in neuropathic pain. Current Opinion in Investigational Drugs (London, England: 2000). 2006;7(1):33-39.‏

Cohen Kenneth, et al. Pharmacological treatment of diabetic peripheral neuropathy. Pharmacy and Therapeutics. 2015;40(6):372.‏

Moore R. Andrew, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews. 2014;4.‏

Lau Torey, Leung Sharon, Lau Wynnie. Gabapentin for uremic pruritus in hemodialysis patients: A qualitative systematic review. Canadian Journal of Kidney Health and Disease. 2016;3(1): 14.

Allameh Zahra, Rouholamin Safoura, Valaie Sonia. Comparison of gabapentin with estrogen for treatment of hot flashes in post-menopausal women. Journal of Research in Pharmacy Practice. 2013;2(2): 64.‏

Chang Connie Y, et al. Gabapentin in acute postoperative pain management. BioMed Research International; 2014.‏

National Institutes of Health, et al. Livertox: Clinical and research information on drug-induced liver injury; 2017.

Available:https://livertox.nih.gov

Mcelroy Susan L, et al. Pharmacological management of binge eating disorder: Current and emerging treatment options. Therapeutics and Clinical Risk Management. 2012;8:219.‏

Kvinesdal Birgit, et al. Imipramine treatment of painful diabetic neuropathy. Jama. 1984;251(13):1727-1730.‏

Marchesi Carlo. Pharmacological manage-ment of panic disorder. Neuropsychiatric Disease and Treatment. 2008;4(1):93.‏

Navarrete Vela. The pharmacological treatment of urinary incontinence. BJU International. 1999;84(9):923-947.‏

Doyle Carolyn A, Mcdougle Christopher J. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues in Clinical Neuro-science. 2012;14(3):263.‏

Rowland DL, De Gouveia Brazao CA, Koos Slob A. Effective daily treatment with clomipramine in men with premature ejaculation when 25 mg (as required) is ineffective. BJU International. 2001;87(4): 357-360.‏

Gloger Sergio, et Al. Panic attacks and agoraphobia: Low dose clomipramine treatment. Journal of Clinical Psycho-pharmacology; 1989.‏

Zhang Ying, et al. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: A meta-analysis. Experimental and Therapeutic Medicine. 2017;14(4):2863-2868.‏

Sklar Grant E, Subramaniam Malar. Acetylcysteine treatment for non–acetaminophen-induced acute liver failure. Annals of Pharmacotherapy. 2004;38(3): 498-501.‏

Ooi Soo Liang, Green Ruth, Pak Sok Cheon. N-acetylcysteine for the treatment of psychiatric disorders: A review of current evidence. BioMed Research International; 2018.‏

El‐Ebiary Ahmad A, et al. N‐acetylcysteine in acute organophosphorus pesticide poisoning: A randomized, clinical trial. Basic, Clinical Pharmacology & Toxicology. 2016;119(2):222-227.‏

Fishbane Steven. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clinical Journal of the American Society of Nephrology. 2008;3(1):281-287.‏

Grant Jon E, et al. Skin picking disorder. American Journal of Psychiatry. 2012;169(11):1143-1149.‏

Umrani Dhananjay N, Goyal Ramesh K. Pharmacology of sildenafil citrate. Indian Journal of Physiology and Pharmacology. 1999;43:160-164.‏

Berman Jennifer R, et al. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. Journal of Sex & Marital Therapy. 2001;27(5):411-420.‏

Vargas-Origel Arturo, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. American Journal of Perinatology. 2010;27(03):225-230.‏

Levien Terri L. Advances in the treatment of Raynaud’s phenomenon. Vascular health and risk management. 2010;6:167.‏